Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 6, 2025Annals of Medicine and SurgeryOpen Access

Rivaroxaban showed no significant difference in major bleeding risk (RR 0.91, P=0.69) but significantly reduced DVT recurrence (OR 0.75, P=0.04) compared to dalteparin.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Dalteparin has traditionally been the first-line treatment for cancer-associated VTE, but direct oral anticoagulants like rivaroxaban may offer comparable efficacy with oral administration convenience.

Does rivaroxaban improve efficacy and safety compared to dalteparin in patients with cancer-associated VTE?

Comparison

Rivaroxaban vs dalteparin

Design

Systematic review and meta-analysis

Authors

BSBibek ShresthaSBSuzit BhusalGKG Kandel

Discussion

Loading...

Member takes

Overview

Rivaroxaban offers comparable safety to dalteparin in cancer-associated VTE; extends RCT evidence supporting oral DOAC preference.

Structured PICO

Does rivaroxaban improve efficacy and safety compared to dalteparin in patients with cancer-associated VTE?

P
Population
Patients with cancer-associated venous thromboembolism (VTE) from 9 studies across multiple countries.
I
Intervention
Rivaroxaban
C
Comparator
Dalteparin
O
Outcome
Recurrent VTE and major bleedinghard clinical

Rivaroxaban is a viable, orally administered alternative to dalteparin for cancer-associated VTE, offering comparable safety for major bleeding and a significant reduction in DVT recurrence.

Cite This Study

Shrestha et al. (2025) studied this question.

synapsesocial.com/papers/6a737d22007d73ca2ffb65fchttps://doi.org/10.1097/ms9.0000000000003008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism2019 · 4 citations
  2. 2A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer2019 · 24 citations
  3. 3Rivaroxaban versus low molecular weight heparin in cancer-associated thrombosis: Assessment of clinical equipoise and bleeding risk from randomized evidence.2026
  4. 4Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis2026
  5. 5Efficacy and safety of rivaroxaban compared with LMWH in patients with cancer-associated thrombosis: A systematic review and meta-analysis of randomized controlled trials.2026